US EditionPublished • loading... • Updated
Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon2
ZEGFROVY, an oral targeted therapy, significantly prolonged progression-free survival over platinum chemotherapy in a multinational Phase 3 trial for EGFR exon 20 NSCLC patients, Dizal said.
Summary by The Billings Gazette
9 Articles
9 Articles
The Billings Gazette+8 Reposted by 8 other sources
Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon2
Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doubletWU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-free, targeted…
·Billings, United States
Read Full ArticleCoverage Details
Total News Sources9
Leaning Left0Leaning Right0Center6Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium